Urogen Pharma (URGN) Projected to Announce Quarterly Earnings on Wednesday

Key Points

• Urogen Pharma is expected to report Q3 2026 results before the market opens on November 4. Analysts project earnings of $0.10 per share and revenue of $90.58 million, compared with the prior quarter’s $0.28-per-share loss and $72.46 million in revenue.
• Wall Street’s overall view is bullish, with eight Buy ratings, one Hold and one Sell, producing a “Moderate Buy” consensus and an average price target of $52.38. Recent targets from Guggenheim and TD Cowen range from $58 to $60.
• URGN opened at $33.75, below its 50-day average of $41.06 but above its 200-day average of $31.15. Insiders sold 65,269 shares worth approximately $3.04 million during the last quarter.

Urogen Pharma (NASDAQ:URGN - Get Free Report) will likely be releasing its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Urogen Pharma to announce earnings of $0.10 per share and revenue of $90.58 million for the quarter. Parties can find conference call details on the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 10:00 AM ET.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The firm had revenue of $72.46 million for the quarter, compared to analysts' expectations of $63.55 million. On average, analysts expect Urogen Pharma to post ($0.20) EPS for the current fiscal year and $3.20 EPS for the next fiscal year.

Urogen Pharma Price Performance

URGN opened at $33.75 on Thursday. The firm has a fifty day moving average price of $41.06 and a 200 day moving average price of $31.15. Urogen Pharma has a 1 year low of $16.50 and a 1 year high of $50.81. The stock has a market cap of $1.65 billion, a P/E ratio of -17.05 and a beta of 1.57.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on URGN shares. Oppenheimer reaffirmed an "outperform" rating on shares of Urogen Pharma in a report on Wednesday. Guggenheim increased their target price on shares of Urogen Pharma from $42.00 to $58.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. TD Cowen raised their target price on Urogen Pharma from $50.00 to $60.00 and gave the company a "buy" rating in a research report on Wednesday, August 5th. The Goldman Sachs Group restated a "neutral" rating and issued a $44.00 price target on shares of Urogen Pharma in a research note on Wednesday, July 15th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Urogen Pharma in a report on Thursday, October 15th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $52.38.

Insider Activity

In related news, insider Mark Schoenberg sold 60,677 shares of Urogen Pharma stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $47.05, for a total value of $2,854,852.85. Following the sale, the insider owned 59,086 shares of the company's stock, valued at approximately $2,779,996.30. This trade represents a 50.66% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Chris Degnan sold 2,202 shares of Urogen Pharma stock in a transaction on Thursday, October 8th. The shares were sold at an average price of $36.69, for a total transaction of $80,791.38. Following the completion of the sale, the chief financial officer directly owned 4,561 shares in the company, valued at $167,343.09. This represents a 32.56% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 65,269 shares of company stock worth $3,037,646 in the last quarter. Corporate insiders own 4.80% of the company's stock.

About Urogen Pharma

UroGen Pharma Ltd. NASDAQ: URGN is a biopharmaceutical company focused on developing and commercializing treatments for cancers of the urinary tract. The company's therapies are designed to deliver medicines directly to the affected area, with the goal of improving drug exposure while limiting systemic side effects.

UroGen's primary commercial product is Jelmyto, a mitomycin-based treatment approved in the United States for adults with low-grade upper tract urothelial cancer. Jelmyto uses UroGen's proprietary RTGel technology, which forms a gel in the urinary tract and enables the sustained local release of mitomycin.

The company has also developed UGN-102, an investigational mitomycin-based reverse thermal gel intended for the treatment of low-grade, intermediate-risk non-muscle-invasive bladder cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.